Author:
Wijting Ingeborg,Rokx Casper,Boucher Charles,van Kampen Jeroen,Pas Suzan,de Vries-Sluijs Theodora,Schurink Carolina,Bax Hannelore,Derksen Maarten,Andrinopoulou Eleni-Rosalina,van der Ende Marchina,van Gorp Eric,Nouwen Jan,Verbon Annelies,Bierman Wouter,Rijnders Bart
Subject
Virology,Infectious Diseases,Immunology,Epidemiology
Reference24 articles.
1. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study;Cahn;Lancet,2013
2. Brief report: dolutegravir plus abacavir/lamivudine for the treatment of HIV-1 infection in antiretrovial therapy-naive patients: week 96 and week 144 results from the SINGLE randomized clinical trial;Walmsley;J Acquir Immune Defic Syndr,2015
3. Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO;Molina;J Int AIDS Soc,2014
4. Clinical benefit of dolutegravir in HIV-1 management related to high genetic barrier to drug resistance;Brenner;Virus Res,2016
5. Marcelin AG, Grude M, Charpentier C, et al. French national survey of resistance to integrase inhibitors shows high differences of resistance selection rate in case of virological failure in a context of routine hospital care (ANRS-AC11 virology network). International Congress of Drug Therapy in HIV infection; Glasgow; Oct 23–26, 2016; abstract O332.
Cited by
104 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献